Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zim LaboratoriesNSE:ZIMLAB -2.00%81 Days Sales Outstanding is 94.51 as of Mar. 2026, which is 8% below its 10-year median of 103.05. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 81/100 and a GF Value™ of ₹102.49 (Fairly Valued). The stock has 6 warning signs investors should review. Among 947 Drug Manufacturers companies, Zim Laboratories ranks worse than 74.02% on this metric.
The historical rank and industry rank for Zim Laboratories's Days Sales Outstanding or its related term are showing as below:
NSE:ZIMLAB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 86.75 Med: 103.05 Max: 140.51
Current: 103.35
During the past 12 years, Zim Laboratories's highest Days Sales Outstanding was 140.51. The lowest was 86.75. And the median was 103.05.
NSE:ZIMLAB's Days Sales Outstanding is ranked worse than 74.02% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs NSE:ZIMLAB: 103.35
Zim Laboratories's Days Sales Outstanding
increased
from Mar. 2025 (89.73) to Mar. 2026 (94.51).
Zim Laboratories (NSE:ZIMLAB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Zim Laboratories Days Sales Outstanding Related Terms
Zim Laboratories Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Zim Laboratories's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ZIMLAB vs ZTS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zim Laboratories Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Zim Laboratories's Days Sales Outstanding falls into.
Zim Laboratories Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zim Laboratories (NSE:ZIMLAB) has a Days Sales Outstanding of 94.51 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Zim Laboratories and its competitors. This is near median its historical median of 103.05. Over the past decade, Zim Laboratories' Days Sales Outstanding has ranged from 86.75 to 140.51. According to the industry distribution chart, Zim Laboratories ranks #701 out of 947 companies in the Drug Manufacturers industry, placing it in the top 74%.
Is Zim Laboratories' Days Sales Outstanding too high?
Zim Laboratories' current Days Sales Outstanding of 94.51 is near median its 10-year median of 103.05. Over the past 10 years, this metric has ranged from a low of 86.75 to a high of 140.51. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Zim Laboratories' value of 94.51 is 31.3% above this industry median. Based on the distribution chart, Zim Laboratories ranks #701 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zim Laboratories has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #701 out of 947 companies for Days Sales Outstanding. This places Zim Laboratories in the lower half of its industry. The industry median Days Sales Outstanding is 71.98. Zim Laboratories' value of 94.51 is 31.3% above this benchmark. Historically, Zim Laboratories' own Days Sales Outstanding has ranged from 86.75 to 140.51 over the past decade. While the company's 10-year median is 103.05 vs. the industry median of 71.98, Zim Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim Laboratories's current Days Sales Outstanding of 94.51 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Zim Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim Laboratories's current Days Sales Outstanding is 94.51, which is near median its own 10-year median of 103.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹102.49, compared to a current price of ₹107.55 — trading 4.9% above its estimated fair value. The current Days Sales Outstanding is 94.51, which is near median its 10-year median of 103.05 and 31.3% above the Drug Manufacturers industry median of 71.98. Zim Laboratories' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Days Sales Outstanding is 94.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued.
The current stock price of ₹107.55 is trading 4.9% above its estimated GF Value™ of ₹102.49.
GuruFocus considers Zim Laboratories to be Fairly Valued.
Key valuation signals for NSE:ZIMLAB:
Days Sales Outstanding: 94.51 (near median its 10-year median of 103.05)
GF Value™: ₹102.49 vs. price of ₹107.55 (4.9% above fair value)
Industry Position: 31.3% above the Drug Manufacturers median (#701 of 947)
No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
81GF Score
Get the complete analysis for NSE:ZIMLAB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZIMLAB has been successfully added to your 
